| Name | Title | Contact Details |
|---|
Bi-Coastal Pharmaceutical Corp is a Red Bank, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Iconix Biosciences is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.
Checkpoint Surgical advances the science and practice of nerve protection and repair to improve the quality of life for patients and physicians.
OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.